Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Optimizing transplantation for MDS

Theo de Witte • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes

Theo de Witte, MD, Radboud University Medical Center, Nijmegen, The Netherlands, discusses stem cell transplantation for the treatment of myelodysplastic syndromes (MDS) and how we can optimize outcomes when using this option. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Theo de Witte

5:03
Transplant Patient Selection & MDS 2020 higlights
Theo de Witte • 5 Mar 2020
2:05
EUMDS Registry
Theo de Witte • 5 Mar 2020
2:18
Theo de Witte: an MDS transplant pioneer
Theo de Witte • 5 Mar 2020
1:59
MDS pathology and comorbidities
Theo de Witte • 5 Mar 2020

Related Videos

2:06
Understanding the role of inflammation and the immunome in MDS pathophysiology
Shahram Kordasti • 5 Apr 2024
2:53
Immune checkpoint inhibitors in MDS: the i4MDS consortium
Shahram Kordasti • 5 Apr 2024
2:37
Allo-SCT in older patients with MDS: selection, donors, and timing
Didier Blaise • 4 Apr 2024
1:08
Chronological age no longer dictates eligibility for allogeneic transplantation in patients with MDS
Didier Blaise • 4 Apr 2024
The content of VJHemOnc is intended for healthcare professionals